HPV Country Profile

Statistics and Data Analytics


cases in 2018



deaths in 2018

Status of National HPV Vaccination Programme

The HPV vaccine is currently not included in Jordan’s national immunization program.


General Information

Human Papillomavirus

Burden of HPV infection:

In Jordan, about 2.3% of people in the general population are estimated to have HPV type 16 or 18 at a given time, which causes approximately 79.4% of invasive cervical cancers in the country. A 2009 study showed that HPV types 16 and 18 were found in 75.6% of women with invasive cervical cancer, and other types were responsible for the rest of these cervical cancer cases.1,4

Burden of cervical cancer: Cervical cancer, caused by HPV, is the thirteenth leading cause of cancer deaths in women in Jordan, causing at least 61 deaths annually among the population of 2.5 million women aged 15 years and older who are at risk for the disease.1,2 Between 2012 and 2018, the number of deaths every year due to cervical cancer more than tripled (19 in 2012 to 61 in 2018), and if decisive action is not taken at the national level, annual deaths due to the disease will double by 2040, reaching 125 deaths per year.3 In Jordan, at least 104 women are newly diagnosed with cervical cancer each year.

2.9 per 100,000 women in Jordan contract cervical cancer annually and 1.8 per 100,000 Jordanian women die due to the disease each year. Among countries in the MENA region (as defined by UNAIDS), Jordan’s death and incidence rates due to cervical cancer are about average. For example, Somalia and Morocco have the highest incidence and mortality rates, with 24.0 and 17.2 women per 100,000 being newly diagnosed with cervical cancer annually and at least 21.9 and 12.6 women per 100,000 dying due to cervical cancer per year, respectively. Whereas Iran, Iraq and Yemen have the lowest (around 2 per 100,000 women are diagnosed per year and about 1 per 100,000 die because of cervical cancer annually).2

Cervical cancer incidence and mortality rate projections
Research and Publications
  1. Maraqa, Bayan, et al. “Prevalence of Abnormal Pap Smears: A Descriptive Study from a Cancer Center in a Low-Prevalence Community.” Asian Pacific Journal of Cancer Prevention : APJCP, vol. 18, no. 11, 2017, pp. 3117–21, doi:10.22034/APJCP.2017.18.11.3117.
  2. Obeidat, B. R., et al. “Awareness, Practice and Attitude to Cervical Papanicolaou Smear among Female Health Care Workers in Jordan.” European Journal of Cancer Care, vol. 21, no. 3, May 2012, pp. 372–76, doi:10.1111/j.1365-2354.2011.01297.x.
  3. Sughayer, Maher A., et al. “Human Papillomavirus Genotypes in Invasive Cervical Cancer in Jordan.” International Journal of Gynecology & Obstetrics, vol. 108, no. 1, 2010, pp. 74–75, doi:10.1016/j.ijgo.2009.08.025.
  4. Malkawi, S. R., et al. Evaluation of Cervical Smears at King Hussein Medical Centre, Jordan, over Three and a Half Years. 2004, https://apps.who.int/iris/handle/10665/119467.
  5. Maaita, M., and M. Barakat. “Jordanian Women’s Attitudes towards Cervical Screening and Cervical Cancer.” Journal of Obstetrics and Gynaecology: The Journal of the Institute of Obstetrics and Gynaecology, vol. 22, no. 4, July 2002, pp. 421–22, doi:10.1080/01443610220141416.
View all publications
  1. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Jordan. Summary Report 27 July 2017. [19 October, 2018]

  2. Cancer Today. (2018, September). Retrieved October 19, 2018, from https://gco.iarc.fr/.

  3. Cancer Tomorrow. (2018, September). Retrieved October 19, 2018, from https://gco.iarc.fr/.

  4. Sughayer, M. A., Abdelhadi, M., Abdeen, G., Otay, L., & Dayeh, T. (2009). Human papillomavirus genotypes in invasive cervical cancer in Jordan. International Journal of Gynecology & Obstetrics, 108(1), 74-75. doi:10.1016/j.ijgo.2009.08.025

Please notify us if you know of other resources, including academic publications, news articles and information that should be added to this page by emailing: hpvmena@gmail.com.